Anti-IL-17F antibodies
This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
1. An isolated fully human monoclonal anti-IL-17F antibody, or fragment thereof, wherein said antibody comprises:
(a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:45,
(b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO:46,
(c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO:47,
(d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO:74,
(e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO:75, and
(f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO:76, wherein said antibody binds IL-17F.
2. The antibody of claim 1 , wherein said antibody does not bind the IL-17A homodimer.
3. The antibody of claim 1 , wherein said antibody is an IgG isotype.
4. The antibody of claim 1 , wherein said antibody is an IgG1 isotype.
5. The antibody of claim 1 , wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:10, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:12 or 103.
6. A pharmaceutical composition comprising the antibody of claim 1 and a carrier.